You are here

Share:

B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia

Summary
Available for licensing from the National Cancer Institute are fully human monoclonal antibodies that were selected from the first human post-alloHSCT antibody library. The library was generated from a time point after transplantation at which antibodies to B-CLL cell surface antigens peaked, thus indicating its therapeutic value.
NIH Reference Number
E-163-2009
Product Type
Keywords
  • B-cell, lymphocytic, leukemia, alloHSCST
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes.  Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST).  However, there is less than a 50% chance of finding a matching bone marrow or blood donor for B-CLL patients.  Other clinically tested targeted therapies such as rituximab and alemtuzumab target both malignant and normal B cells, resulting in immunosuppression.

Available for licensing are fully human monoclonal antibodies that were selected from the first human post-alloHSCT antibody library.  The library was generated from a time point after transplantation at which antibodies to B-CLL cell surface antigens peaked, thus indicating its therapeutic value.  Utilizing phage display, the investigators generated a panel of fully human monoclonal antibodies that strongly bind to the same epitope on a B-CLL cell surface antigen.   Weaker binding to normal B cells, but not to other lymphocytes, was observed.  These fully human monoclonal antibodies provide readily available treatment that selectively targets malignant B cells.

Potential Commercial Applications
  • B-cell chronic lymphocytic leukemia therapeutics
  • Method to inhibit the growth of malignant B-cells
  • Method to detect B-cell tumors
Competitive Advantages
  • Selective targeting of malignant B-cell surface antigens that are minimally non-damaging to non-diseased cells
  • Readily available therapeutics without the need for bone marrow or blood transplantation
Inventor(s)

Christoph Rader (NCI)

Development Stage
Publications

S Baskar, et al. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. [PMID 19667400]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 61/178,688, Filed 15 May 2009
Therapeutic Area
Updated
Tuesday, April 17, 2018